Get the Stockscreener App
4.33
8.84%
-0.42
After Hours:
4.37
0.04
+0.92%
Omniab Inc stock is traded at $4.33, with a volume of 1.70M.
It is down -8.84% in the last 24 hours and up +116.50% over the past month.
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.
See More
Previous Close:
$4.75
Open:
$4.78
24h Volume:
1.70M
Relative Volume:
1.45
Market Cap:
$629.54M
Revenue:
$28.94M
Net Income/Loss:
$-54.29M
P/E Ratio:
-9.3178
EPS:
-0.4647
Net Cash Flow:
$-26.02M
1W Performance:
-3.13%
1M Performance:
+116.50%
6M Performance:
+139.23%
1Y Performance:
+170.62%
1-Day Range:
$4.28
$4.78
1-Week Range:
$4.28
$5.43
52-Week Range:
$1.30
$5.43
Omniab Inc Stock (OABI) Company Profile
Name
Omniab Inc
Sector
Industry
Phone
510-250-7800
Address
5980 HORTON STREET, EMERYVILLE
Compare OABI vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OABI
Omniab Inc
|
4.33 | 625.18M | 28.94M | -54.29M | -26.02M | -0.4647 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Omniab Inc Stock (OABI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-29-23 | Initiated | RBC Capital Mkts | Outperform |
| Apr-21-23 | Initiated | The Benchmark Company | Buy |
| Apr-13-23 | Initiated | Craig Hallum | Buy |
| Feb-22-23 | Initiated | Cowen | Outperform |
| Feb-13-23 | Initiated | H.C. Wainwright | Buy |
| Dec-20-22 | Initiated | Truist | Buy |
| Dec-16-22 | Initiated | Credit Suisse | Outperform |
| Nov-29-22 | Initiated | SVB Leerink | Outperform |
| Nov-28-22 | Initiated | Stifel | Buy |
View All
Omniab Inc Stock (OABI) Latest News
OmniAb Inc. OABI Stock Holds Support As Traders Weigh Weak Margins - StocksToTrade
OmniAb Inc. Stock Holds Range As Traders Weigh Deep Losses Against Strong Balance Sheet - timothysykes.com
Biotech Stocks At 52-Week HighsOABI +13%, FRNM, EXEL, FTH, LFST - RTTNews
OmniAb Company Profile & Introduction - Moomoo
OABI Looks 50.3% Overvalued on GF Value™ - GuruFocus
Is OmniAb (OABI)’s Eli Lilly (LLY) Partnership a Game Changer for OABI? - finance.yahoo.com
OmniAb to Participate in Upcoming Investor Conferences - Yahoo Finance
OmniAb (OABI) Earnings Reading: EPS Beats Its Estimate at the Close; Post-Earnings: The Share Price Adds 8.78%EPS Surprise History - vinanet.vn
OmniAb (OABI) Results at a Glance: The Available Earnings Metric Delivers a Beat in the Latest Session; Post-Report: The Market Price Moves 0.70% Higher at the CloseEarnings Stability Report - vinanet.vn
OmniAb (OABI) Quarter in Focus: The Available Earnings Metric Delivers a Beat; Share Move: The Market Price Moves 1.79% Higher at the CloseBanking Earnings Report - vinanet.vn
OmniAb secures up to $370m Lilly deal for ion channel program - BioXconomy
Truist Financial Maintains OmniAb(OABI.US) With Buy Rating - Moomoo
Eli Lilly stock approaches $1,314 resistance as OmniAb drug discovery partnership fuels rally - Traders Union
OmniAb signs $370 million ion channel discovery deal with Eli Lilly - The Pharma Letter
OmniAb boosts 2026 cash guidance after milestone-rich Eli Lilly deal validates its biotech platform. - Pluang
M&A Roundup: LEO Pharma Acquires Dersimelagon, BioMarin Acquires Alesta, OmniAb Enters collaboration with Eli Lilly, Chugai and GSK Enter License Agreement for AID351 - Pharmaceutical Executive
Analysts Offer Insights on Healthcare Companies: OmniAb (OABI), Neurocrine (NBIX) and Evaxion Biotech (EVAX) - The Globe and Mail
OmniAb: Lilly-Style Partners Paying Attention To This Early-Stage Biotech (NASDAQ:OABI) - Seeking Alpha
Craig-Hallum Maintains OmniAb(OABI.US) With Buy Rating, Maintains Target Price $7 - Moomoo
OmniAb Jumps 18% as Lilly Deal Lifts Cash Outlook - TradingView
Eli Lilly Signs $370 Million Ion Channel Deal With OmniAb, Sending Shares Surging - finance.biggo.com
OABI Reiterates by HC Wainwright & Co. -- Price Target Maintained at $11.00 - GuruFocus
Lilly taps OmniAb for ion channel discovery in deal worth up to USD 370m - AllSci
Lilly to pay up to $370M for OmniAb collab; Slate, Fulcrum forge reverse merger - Endpoints News
OmniAb Raises 2026 Financial Guidance - BioSpace
$OmniAb (OABI.US)$ - Moomoo
OmniAb Inc. (OABI) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
OmniAb (OABI) Stock Pops As Earnings Beat Resets Growth Outlook - timothysykes.com
Why Is Omniab Stock Rallying After Eli Lilly Deal? - Benzinga
OmniAb (OABI) Stock Surges After Big Q2 Earnings Beat - StocksToTrade
Why is OmniAb stock surging today? By Investing.com - Investing.com South Africa
OABI Looks 15.8% Overvalued on GF Value™ - GuruFocus
Why is OmniAb stock surging today? - Investing.com
OmniAb (OABI) Jumps As Earnings Beat Fuels Bullish Outlook - StocksToTrade
Lilly pens $370M deal with OmniAb for ion channel collab, but details remain vague - Fierce Biotech
OmniAb raises 2026 cash guidance to $49-$53 million range - scanx.trade
OmniAb lifts 2026 cash outlook following licensing momentum - Yahoo Finance
OmniAb raises 2026 cash guidance on licensing activity By Investing.com - Investing.com Canada
OmniAb Announces Global Collaboration and License Agreement for Ion Channel Program with Eli Lilly & Company - Finviz
OmniAb partners with Eli Lilly on ion channel program By Investing.com - Investing.com Canada
OmniAb raises 2026 cash guidance on licensing activity - Investing.com
OmniAb, Inc. And Eli Lilly And Company Announce Global Collaboration And License Agreement For Ion Channel Program - marketscreener.com
Whitefort Capital group reports 7.1% OmniAb (OABI) ownership in amended filing - Stock Titan
OmniAb (OABI) Q2 2026 Earnings Call Transcript - AOL.com
Dimensional Fund Advisors LP Has $2.74 Million Stake in OmniAb, Inc. $OABI - marketbeat.com
OmniAb Inc (OABI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
OABI Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
New Forecasts: Here's What Analysts Think The Future Holds For OmniAb, Inc. (NASDAQ:OABI) - simplywall.st
OmniAb (NASDAQ:OABI) Sets New 1-Year HighTime to Buy? - MarketBeat
Is Now The Time To Look At Buying OmniAb, Inc. (NASDAQ:OABI)? - Moomoo
HC Wainwright Forecasts OmniAb's Q3 Earnings (NASDAQ:OABI) - marketbeat.com
Omniab Inc Stock (OABI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):